secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2024-05-03T23:59:59+00:00
Accession:  0001654954-24-005552
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences receives Nasdaq bid price deficiency notice; has until Oct 30 to regain compliance
--------------------------------------------------------------------------------

- Received Nasdaq notice on May 3, 2024 for closing bid price below $1.00 for 30 consecutive trading days.
- Has 180 calendar days, until October 30, 2024, to regain compliance with Minimum Bid Price Requirement.
- To cure: bid price must close at or above $1.00 for at least 10 consecutive business days before deadline.
- If not cured by Oct 30, may qualify for additional 180-day period if it meets other listing standards.
- Company intends to monitor bid price and consider options including a potential reverse stock split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424005552/0001654954-24-005552-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424005552/ndra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-005552

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer